

Cancer cachexia in adult patients: ESMO Clinical Practice Guidelines■.

Title: Cancer cachexia in adult patients: ESMO Clinical Practice Guidelines■.

Publication year: 2021

Journal: ESMO open

Authors: Department of Medicine I, Medical Center - University of Freiburg Faculty of Medicine, University of Freiburg, Freiburg, Germany.

Society: European Society for Medical Oncology

Origin country: International (Europe)

Target countries: Europe

DOI: 10.1016/j.esmoop.2021.100092

PMID: 34144781

Source: <https://pubmed.ncbi.nlm.nih.gov/34144781/>

ESMO Open ESMO Open 3084 esmo 101690685 ESMO Open 2059-7029 Elsevier PMC8233663 PMC8233663.1 8233663 8233663 34144781 10.1016/j.esmoop.2021.100092 S2059-7029(21)00049-1 100092 1 Special Article Cancer cachexia in adult patients: ESMO Clinical Practice Guidelines ■ Arends J. 1 Strasser F. 2 3 Gonella S. 4 5 Solheim T.S. 6 7 Madeddu C. 8 Ravasco P. 9 10 11 Buonaccorso L. 12 de van der Schueren M.A.E. 13 14 Baldwin C. 15 Chasen M. 16 17 18 Ripamonti C.I. 19 on behalf of the ESMO Guidelines Committee * clinicalguidelines@esmo.org 1 Department of Medicine I, Medical Center – University of Freiburg Faculty of Medicine, University of Freiburg, Freiburg, Germany 2 Integrated Cancer Rehabilitation and Cancer Fatigue Clinic, Klinik Gais/Kliniken Valens 3 Clinic Medical Oncology and Hematology, Cantonal Hospital St Gallen, St Gallen, Switzerland 4 Direction of Health Professions, Azienda Ospedaliero Universitaria Città della Salute e della Scienza of Turin, University of Turin, Turin, Italy 5 Department of Public Health and Pediatrics, University of Turin, Turin, Italy 6 Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway 7 Cancer Clinic, Trondheim University Hospital, Trondheim, Norway 8 Medical Oncology Unit, Azienda Ospedaliero Universitaria Cagliari, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy 9 Immuno-Hemotherapy and Oncology, University Hospital of Santa Maria, CHULN, Lisbon, Portugal 10 Center for Interdisciplinary Research in Health, Universidade Católica Portuguesa, Lisbon, Portugal 11 University of Lisbon, Portugal 12 Psycho-Oncology Unit, Azienda USL-IRCCS, Reggio Emilia, Italy 13 Department of Nutrition, Dietetics and Life Style, School of Allied Health, HAN University of Applied Sciences, Nijmegen, The Netherlands 14 Division of Human Nutrition and Health, Wageningen University & Research, Wageningen, The Netherlands 15 Department of Nutritional Sciences, King's College London, London, UK 16 Department of Medicine, University of Toronto, Toronto, Canada 17 Department of Family Medicine, McMaster University, Hamilton, Canada 18 William Osler Health Services, Brampton, Canada 19 Oncology-Supportive Care in Cancer Unit, Department of Onco-Haematology, Fondazione IRCCS Istituto Nazionale dei Tumori Milano, Milan, Italy * Correspondence to: ESMO Guidelines Committee, ESMO Head Office, Via Ginevra 4, CH-6900 Lugano, Switzerland 6 2021 16 6 2021 6 3 379522 100092 16 06 2021 29 06 2021 02 04 2024 © 2021 The Author(s) 2021 <https://creativecommons.org/licenses/by-nc-nd/4.0/> This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>). Corrigendum to 'Towards a novel approach guiding the decision-making process for anticancer treatment in patients with advanced cancer: framework for systemic anticancer treatment with palliative intent' 7 6 19 10 2022 100614 ESMO Open 10.1016/j.esmoop.2022.100614 PMC9808468 36567081 Highlights • This ESMO Clinical Practice Guideline provides key recommendations for managing cancer-related cachexia.

It covers screening, assessment and multimodal management of cancer cachexia.

All recommendations were compiled by a multidisciplinary group of experts.

Recommendations are based on available scientific data and the author's expert opinion.

Cachexia remains an underdiagnosed and undertreated, complex condition which includes 'objective' components (e.g. inadequate food intake, weight loss, inactivity, loss of muscle mass and metabolic derangements, inducing catabolism) 1 , 2 and 'subjective' components (e.g. anorexia, early satiety, taste alterations, chronic nausea, distress, fatigue and loss of concentration). Approximately half of all patients with advanced cancer experience cachexia.

Comprehensive treatment requires a multitargeted and multidisciplinary approach aimed at evaluating the objective signs and relieving the symptoms. The primary goal is to meet the physiological and psychological needs of the patient. This includes providing energy, nutritional substrates and anabolic stimuli, as well as compassionate support to address dysfunctions associated with the emotional and social aspects of eating. Nutritional and metabolic interventions range from dietary counselling to pharmacological agents and parenteral nutrition (PN). The invasiveness of an intervention needs to be chosen and tailored, weighing the benefits and risks for each individual patient. This is of increasing importance with advancing disease and when approaching end of life. In this sense, nutrition is an essential component of supportive, rehabilitative and palliative care. During the patient's trajectory towards end of life, however, the focus of nutritional care needs to change. During anticancer treatment, patients should be offered all available nutritional therapeutic options, if required, whereas during the last weeks of life, care should focus increasingly on immediate symptomatic relief (Figure 1). Figure 1 Invasiveness of interventions relative to expected survival.

In general, if anticancer treatment is effective, this often results in an improvement in cachectic signs and symptoms, 3 while ineffective anticancer treatment may increase catabolism and aggravate cachexia. 4

This European Society for Medical Oncology (ESMO) Clinical Practice Guideline (CPG) on cancer cachexia has been designed for medical oncologists who frequently care for patients with cancer cachexia in their clinical practice. The goal is to provide answers to questions regarding the diagnosis and treatment of cachexia-related physical and psychological problems, relying on evidence-based information whenever possible. A similar approach has recently been published by the American Society of Clinical Oncology (ASCO). 5

This CPG provides recommendations on overt cachexia as well as at-risk settings. Evidence to support these recommendations has been derived from trials studying the evolution of the signs and symptoms of cachexia. Whereas today we define cachexia on a pathophysiological basis to be malnutrition in the presence of disease-related metabolic alterations, 6 , 7 , 8 historically, clinical trials used varying and inconsistent combinations of inclusion criteria. A summary of inclusion criteria for all clinical trials, guidelines and systematic review articles reported in this CPG is therefore provided for reference in Supplementary Tables S1, S2 and Supplementary Figures S1A–S1C , available at <https://doi.org/10.1016/j.esmoop.2021.100092> .

- Regular nutritional screening and nutritional support, including (if necessary) enteral nutrition or PN, is recommended in all patients receiving anticancer treatment and in those with an expected survival of more than a few months [V, B].

In patients with an expected survival of less than a few months, a decrease in the invasiveness of nutritional interventions is recommended, with dietary counselling and oral supplements preferred, if possible [V, B].

In patients with an expected survival of less than a few weeks, comfort-directed care is the recommended approach, including alleviating thirst, eating-related distress and other debilitating symptoms [V, B].

Weight loss with depletion of fat stores and muscle mass frequently develop in patients with advanced cancer and may be the first signs leading to the diagnosis of a malignancy. A number of pathophysiological derangements may result in weight loss and several factors often occur at the same time, including impaired food intake, reduction in physical activity and its associated anabolic effects as well as metabolic changes leading to systemic inflammation and activation of catabolism (see Figure 2). Patients with depleted resources are at an increased risk of anticancer treatment-related toxicity and a lower quality of life (QoL); toxicity results in shorter treatment times, lower dose intensity, lower response rates, increased surgical complications and higher mortality. 7 Figure 2 The complexity of causes contributing to weight loss in patients with cancer.

Although used since the 19th century, a disconcerting number of definitions have been proposed for the term 'malnutrition'. To avoid confusion, we recommend following the recent suggestion of the Global Leadership Initiative in Malnutrition (GLIM) 8 that defines malnutrition by the presence of a positive malnutrition screening test, one of a list of phenotypical and one of two aetiological criteria (see Table 1). Aetiological criteria are used to differentiate starvation-type (with protein-sparing metabolism 9) from cachexia-type or disease-associated malnutrition, characterised by accelerated protein breakdown and the hallmark of muscle loss driven by metabolic changes, most notably systemic inflammation. 6 , 10 , 11 Table 1 Definitions of major terms

MST, Malnutrition Screening Tool; MUST, Malnutrition Universal Screening Tool; NRS-2002, Nutrition Risk Screening 2002; SARC-F, Strength, Assistance with walking, Rise from a chair, Climb stairs and Falls; SNAQ, Short Nutritional Assessment Questionnaire.

Tissue injury induces inflammation; 12 in cancer, malignant and stromal immune cells may contribute to a chronic inflammatory state 13 leading to complex catabolic sequelae. 14 Systemic inflammation has been extensively and reliably associated with poor clinical outcome. A widely validated and simple score to categorise systemic inflammation is the modified Glasgow Prognostic Score, based on C-reactive protein and serum albumin (C-reactive protein normal: 0; raised C-reactive protein and normal albumin: 1; raised C-reactive protein and low albumin: 2). This score is highly prognostic of clinical outcome. 15

Thus, the pathophysiology of cachexia is currently understood as host-tumour interactions redirecting metabolism and driving the brain to reduce appetite, cause alterations in taste and smell, impact gastrointestinal (GI) autonomic function, induce fatigue and decrease daily physical activity (see Section 2 of the Supplementary Material , available at <https://doi.org/10.1016/j.esmoop.2021.100092>). While inadequate food intake is a major driver of weight loss, 7 metabolic changes and reduced activity contribute to loss of muscle mass. 16

During the last decade, low muscle mass (sarcopenia; see definition in Table 1 17) has been identified as a central factor impacting clinical outcome, and anticancer agents have been recognised as an important cause of sarcopenia. 18 In clinical practice, it is highly relevant that loss of muscle strength and muscle mass may appear early and before the occurrence of a clinically apparent weight loss and that it may coexist with obesity and hence be present in patients with a high body mass index (sarcopenic obesity). 19

Cachexia may evolve over time and it has been proposed to differentiate early phases without discernible weight loss (pre-cachexia) from advanced or refractory stages 6 (see Figure 3). In cachectic patients, the most common GI symptoms are anorexia and early satiety, nausea, bloating, taste alterations, xerostomia, dysphagia and constipation. In addition, other secondary nutrition impact symptoms may occur, such as breathlessness, severe fatigue, etc. Nutrition impact symptoms are commonly experienced and are associated with a poor QoL and performance status (PS). 20 Figure 3 Evolution of cancer cachexia.

- Defining cachexia as disease-related malnutrition based on the GLIM definition of malnutrition and the presence of systemic inflammation is recommended [V, A].

To ensure access to adequate nutritional and metabolic care for all patients, it is important to: • Detect at-risk patients by routinely implementing a standardised screening procedure.

Assess all at-risk patients for their nutritional and metabolic status as well as all impairments endangering this status. 7

Nutritional risk screening should be carried out regularly in all cancer patients undergoing anticancer treatment and in those with an expected survival of more than a few (i.e. 3-6) months. In patients with an expected survival of less than a few months, screening for eating-related distress should be carried out (Figure 4). Figure 4 Screening and assessment of nutritional and metabolic risk for cachexia.

GI, gastrointestinal; MNA-sf, Mini Nutritional Assessment short form; MST, Malnutrition Screening Tool; MUST, Malnutrition Universal Screening Tool; NRS-2002, Nutrition Risk Screening 2002; PG-SGA, Patient-Generated Subjective Global Assessment; SNAQ, Short Nutritional Assessment Questionnaire.

While there is no general agreement on the 'best' screening tool, 21 , 22 the following are suggested: Malnutrition Universal Screening Tool (MUST), Nutrition Risk Screening 2002 (NRS-2002), Short Nutritional Assessment Questionnaire (SNAQ) and the Malnutrition Screening Tool (MST). 21 Other more complex tools like the Patient-Generated Subjective Global Assessment (PG-SGA) may be included in assessment procedures.

All patients diagnosed as being at-risk following malnutrition screening should be referred to a nutrition expert for assessment of nutritional and metabolic status and evaluation of food intake impairment and GI function. 7 Assessing nutritional status should include objective assessment of the following (see Table 2 for recommended parameters): • Body weight (BW).

Weight change during the preceding months.

Body composition with a focus on muscle mass. 6

Food intake with a focus on energy and protein.

PS [Eastern Cooperative Oncology Group (ECOG)/World Health Organization (WHO)].

Information regarding the presence and degree of systemic inflammation. 7

Parameters of comprehensive cachexia assessment and recommended tools

ADL, activities of daily living; BIA, bioelectrical impedance analysis; BW, body weight; CT, computed tomography; DEXA, dual X-ray absorptiometry; ECOG, Eastern Cooperative Oncology Group; ESAS, Edmonton Symptom Assessment System; EORTC, European Organisation for Research and Treatment of Cancer; FAACT, Functional Assessment of Anorexia/Cachexia Treatment; GI, gastrointestinal; PG-SGA, Patient-Generated Subjective Global Assessment; PS, performance status; QLQ-CAX24, cachexia-specific quality of life questionnaire; WHO, World Health Organization.

If available and appropriate, depending on resources available and the patient's capability.

An assessment of factors that are impeding or that might interfere with maintaining nutritional status should include evaluation of: • Nutrition impact symptoms, such as anorexia, nausea, taste and smell alterations, mucositis, constipation, dysphagia, chronic pain, abdominal pain (e.g. cramping) and diarrhoea, as well as aspects of GI function potentially responsible for these symptoms.

Fatigue, physical activity, shortness of breath and psychosocial distress. 7

Assessment should focus on modifiable factors that can be addressed by an intervention. The systematic use of a nutritional impact checklist has been shown to trigger more therapeutic interventions, leading to better symptom control and subsequently to a better nutritional intake. 23 Based on these findings, a tailored intervention can be started, including nutritional advice, alleviating nutritional impact factors and targeting any other factors that may hinder an adequate nutritional intake (such as social support or financial difficulties).

- Standardised screening for nutritional risk at regular intervals is recommended for all patients undergoing anticancer treatment and those with a life expectancy of at least a few (i.e. 3-6) months; a validated screening tool should be applied [V, B].

Offering supportive nutritional advice and education about cachexia, as well as psychological and palliative support, is recommended for all patients experiencing eating-related distress [V, B].

Patients found to be at no immediate risk of malnutrition by screening should be re-screened at regular intervals (typically every 3 months or at staging for anticancer treatment) or, in cases where anticancer treatment with a high risk of inducing malnutrition is planned (e.g. combined-modality treatments, high-dose chemotherapy, highly emetogenic agents), prophylactic nutritional support should be considered [V, B].

For patients identified as being at nutritional risk, an objective assessment of nutritional and metabolic status (including weight, weight loss, body composition, inflammatory state, nutritional intake and physical activity) and examination for the presence of factors interfering with the maintenance or improvement of this status (including nutrition impact symptoms, GI dysfunction, chronic pain and psychosocial distress) is recommended. Repeating nutritional assessments at regular intervals, typically monthly, is also recommended to guide multi-component anti-cachexia treatment [V, B].

The relative importance of cachexia-related subjective and objective signs and symptoms may change during the trajectory of the disease; changes in body resources and metabolic pattern as well as impairment of physical performance are essential targets in patients undergoing anticancer treatment, but they lose their importance near end of life. Debilitating symptoms, however, need to be treated and alleviated as much as possible throughout the life of every patient with the involvement of his/her family members and caregivers.

Predicting the overall survival (OS) and end of life of individual patients is inherently difficult, inaccurate and often overly optimistic. 24 Probability estimates (i.e. prediction of the chances of a patient being alive at a certain time point) are more accurate, 25 as are simple scores based on inflammatory markers. 26

Dealing with uncertainties in prognosis requires continuous, honest and empathic communication with the patient and his/her caregivers as well as comprehensive discussions among all members of the medical team to recognise and repeatedly re-evaluate the indication for individual anti-cachexia interventions, given that each intervention is associated with different risks and burdens. Table 3 provides a summary of key criteria to consider when discussing the initiation of nutritional interventions with the patient and family/caregivers. Table 3 Criteria to consider when deciding on nutritional and metabolic interventions

Given the complex and multifaceted contributors to cachexia, anti-cachexia treatment must be based on a comprehensive assessment of the patient's situation and an evaluation of reasonable, available treatment options, resulting in a personalised, multitargeted and multimodal approach. 27

Food intake may be compromised by many factors and secondary to nutrition impact symptoms, some of which may be amenable to treatment. If, after alleviating these factors, food intake is still inadequate, nutrition-based interventions should be initiated.

Compared with providing energy and nutrients by nutritional interventions, modulating metabolic derangements is more complex. The evolution of insulin resistance 28 and anabolic resistance 29 impair the maintenance of whole-body muscle mass. Thus, interventions to decrease catabolism and increase anabolic pathways include the provision of adequate amounts of energy and proteins; muscle training; pharmacological agents to increase appetite, diminish systemic inflammation and stimulate muscle growth; and psychosocial interactions to alleviate distress.

When anticancer treatment is offered to a cachectic patient, in addition to carefully adjusting the dosing, the intensity of multimodal supportive management needs to be enhanced, encompassing nutrition, physical exercise, anti-catabolic and anti-inflammatory treatment, as well as psychological and social support. In the cachectic cancer patient who is physically unfit for further oncological therapy, a key challenge is to decide whether to maintain or reduce the intensity of multimodal supportive management. Nutritional support and physiotherapy may be offered on an individual basis while carefully monitoring individual goals and QoL. During the last weeks of life, it is essential to provide relief from eating-related distress and weight loss-related distress, strategies to cope with impending death and compassionate communication with patients and family.

- Every patient with cachexia should be offered interventions with the goal of either improving or alleviating the consequences of cachexia [II, B].

Cachexia treatment requires a multimodal approach aimed at relieving symptoms impacting on food intake, ensuring adequate energy and nutrient intake, minimising catabolic alterations, supporting muscle training and offering psychological and social support [II, B].

During anticancer treatment and in patients with a life expectancy of more than a few (i.e. 3-6) months, interventions to both antagonise deterioration of body resources and metabolism, and to alleviate debilitating symptoms, are recommended [IV, B].

If expected survival is less than a few (i.e. 3-6) weeks, focussing on anti-cachexia interventions aimed at alleviating distressing symptoms like thirst, nausea, vomiting and dysphagia, and psychological and existential distress, as well as distress to family members, is recommended [IV, B].

In situations where it is difficult to decide on appropriate anti-cachexia intervention strategies, a tentative intervention for a limited period may be considered to evaluate the likelihood of improvement [IV, C].

In patients undergoing anticancer therapy and/or with an expected survival of at least a few months, ensuring an adequate energy and nutrient intake should be pursued vigorously (see section on nutritional requirements). Cancer patients who cannot eat adequate amounts of food should receive nutritional support as an essential component of best supportive care to improve food intake, BW and QoL. 30 , 31 , 32 Nutritional support in patients able to eat should be based on dietary counselling, guidance on choosing high-energy, high-protein foods, enriching foods (e.g. by adding fat/oils, protein powder) and use of oral nutritional supplements (ONSs). If this proves inadequate, tube feeding should be offered if the lower GI tract is working, otherwise PN is the method of choice. Separate routes of feeding may be combined for optimal effect 7 (Figure 5). Figure 5 Choosing nutritional intervention options.

Purple: symptom; turquoise: nutritional interventions; white: other aspects of management.

EN, enteral nutrition; GI gastrointestinal; NTF, nasogastric tube feeding; ONS, oral nutritional supplement; PEG, percutaneous endoscopic gastrostomy; PN, parenteral nutrition.

In patients not receiving anticancer therapy with an expected survival of less than a few months, nutritional interventions with low risks/burdens for the patient (e.g. counselling and ONSs) are preferred. Very few trials have compared different modes or amounts of nutritional support. In one trial, which randomised patients with severely compromised food intake and a limited survival of 1-4 months to supplemental PN or oral feeding, PN did not improve QoL or survival but increased adverse events. 33 Similarly, another trial which randomised patients in the end-of-life setting to PN or fluids only showed that PN did not affect median survival. 34 During the last weeks of life, nutritional interventions are rarely indicated. 7 Given the potential risks of enteral nutrition and PN (see sections on tube feeding and PN), these interventions should be considered as high-risk compared with low-risk interventions such as counselling and ONSs.

The aim of nutritional support is to ensure adequate intake of energy and nutrients by enabling the patient to eat normal food, enjoy eating and participate in meals with others as a component of social life. 7 It may be difficult or even impossible to achieve tissue accretion without physical activity and within the context of active systemic inflammation; therefore, these problems need to be addressed simultaneously.

While resting energy expenditure may be increased in cachexia, total energy expenditure is often normal (25-30 kcal/kg BW/day) because of corresponding reductions in physical activity, 7 but may be unpredictably low or high in some patients. 35 Even increased energy and protein intake may not be able to attenuate weight loss in all patients. Given the presence of anabolic resistance in older subjects and in chronic diseases, higher than normal amounts of protein (at least 1.2 and possibly up to 2 g/kg BW/day) may be required to balance protein synthesis. 36 , 37 , 38

Fat utilisation in weight-losing cancer patients is very efficient and may cover a major part of resting energy expenditure, 39 , 40 whereas carbohydrate utilisation is impaired in the presence of systemic inflammation and insulin resistance. In addition, fats are energy-dense and allow for feeding of smaller volumes. Compared with standard food, an isonitrogenous, isocaloric, ketogenic diet low in carbohydrates maintains nitrogen balance and whole-body protein turnover rates. 41 In a randomised controlled trial (RCT) carried out in malnourished cancer patients, a high-fat diet improved weight control, fat-free mass and body mass compared with normal food. 42

It is unreasonable to expect an increase or stabilisation in weight if nutritional needs are not met. As a good example, two systematic reviews have shown that dietary counselling is generally effective in increasing dietary intake, BW and QoL in patients undergoing radiotherapy, with some suggestion that dietary counselling may also improve nutrition impact symptoms, complications, response to anticancer treatment and survival. 43 , 44

ONSs are a balanced mixture of macro- and micro-nutrients available as liquid feeds, puddings and powdered formulations reconstituted with milk or water. They are available in a range of different presentations, flavours and formulations, including fibre-containing and milk-, juice- or yoghurt-like products. In general, dietary counselling with ONSs, when necessary, is effective for inducing weight gain and increasing dietary intake. However, most trials on this topic were hampered by poor methodological quality, specifically from inadequate reporting of actual dietary intake and not reaching recommended dietary intakes. 32 , 45 Three systematic reviews reported that providing standard ONSs without dietary counselling was not effective. 43 , 44 , 46 As such, ONSs are best used as an adjunct to a therapeutic diet and counselling by a professional dietician. 46 A meta-analysis of patients undergoing chemotherapy showed positive effects of dietary counselling on weight gain with or without ONSs. 32 Two systematic reviews focusing on dietary counselling

and ONSs in malnourished patients reported positive effects on energy intake, weight gain and some aspects of QoL (e.g. emotional functioning, loss of appetite and global QoL) but noted that evidence was weak due to the poor methodological quality of included trials. 30 , 47

In cancer cachexia, n-3 fatty acids have been studied, particularly for their anti-inflammatory properties, and are available as a component of specialised ONSs, usually also enriched in protein (N3P-ONSs). Several randomised trials have been published on the effects of N3P-ONSs in cancer patients. 32 , 47 , 48 , 49 , 50 Overall, studies were heterogeneous and inadequately powered to show effects on treatment toxicity or survival. No negative effects of the supplements were reported. Most trials suggested benefits of N3P-ONSs on weight, lean body mass and some aspects of QoL when given to patients receiving radiotherapy, chemotherapy or chemoradiotherapy. However, when given to patients not receiving anticancer therapy, no benefit of N3P-ONSs was detected. 51

Dysphagia due to obstruction, motility dysfunction or mucosal inflammation may compromise or prevent normal food intake and thus is an indication for tube feeding to circumvent the defect. Patients with head and neck or upper GI cancers are at particular risk of dysphagia due to obstructing tumours as well as severe mucositis induced by aggressive treatment (e.g. combined-modality treatment). It is critical to recognise the emergence of dysphagia early and to respond in a timely and individually appropriate way to safeguard adequate feeding. This may include diagnostic procedures to classify and grade swallowing deficits, involving a speech therapist, specialised dietary counselling and products either via nasogastric tube feeding (NTF) or percutaneous tube feeding [e.g. percutaneous endoscopic gastrostomy (PEG)]. 7 , 52

Tube feeding may be associated with potentially serious complications, including mechanical (e.g. tube blockage), GI (e.g. diarrhoea), infectious (e.g. aspiration pneumonia) and metabolic (e.g. refeeding syndrome) complications. 53

Short-term RCTs have shown that the metabolic efficacy and complication rates of enteral nutrition and PN are similar. 54 , 55 As the enteral route is more physiological, safer and less expensive, it represents the first option if there is no severe impairment of GI function (Figure 5). In some settings, supplemental PN should be preferred over tube feeding; for example, if patients are suffering from nausea, vomiting, abdominal discomfort or severe diarrhoea. Tube feeding may be ineffective due to frequent dislodging; in particular, tube feeding may not prevent aspirations in patients with dysphagia. Given the lack of reliable clinical evidence of superior outcome for either method, it has been proposed that patient preference be considered when deciding on the feeding method. 56 Some patients strongly prefer an intravenous route over tube feeding, 56 , 57 especially if a patient has already had a central venous catheter inserted.

Results from observational trials and RCTs comparing early tube feeding to oral nutrition in patients with head and neck cancer are heterogeneous, possibly due to the different oral nutrition regimens used in the control groups as well as a lack of stratification of patients by risk scores for malnutrition and dysphagia. 58 Appropriate prediction and careful monitoring of food intake in order to identify the need for initiation of enteral feeding are recommended by European and Canadian guidelines. 7 , 59

Several RCTs have compared NTF and PEG in head and neck cancer patients requiring nutritional support for ≥ 1 month. PEG resulted in better nutritional parameters after 6 weeks of treatment but not later. 60 , 61 Meta-analyses have also reported no significant differences in the overall complication rates between NTF and PEG, 62 even though tube dislodgement was more frequent with NTF and dysphagia was more frequent with PEG. 63 Resolution of dysphagia is impaired with long-term tube feeding.

In patients with severely compromised GI function, it may be impossible to ensure adequate nutrition by the oral or enteral route. PN and home PN are being widely used in patients with

advanced cancer, both in patients still receiving or no longer receiving anticancer treatments, although evidence to support PN in patients with advanced cancer is weak. 33 , 64 , 65 , 66 It appears obvious that a prolonged, severely reduced tolerance of food may compromise clinical outcome, and in these settings, PN might improve QoL and possibly survival. A recent systematic review assessing the effectiveness of home PN in people with malignant bowel obstruction included only observational studies, reported a high risk of bias and graded the certainty of evidence to be very low for improving survival and QoL. 67 Another systematic review found that PN in patients with advanced cancer was understudied and that the level of evidence was weak. 68 The PS and Glasgow Prognostic Score impact strongly on survival in patients with advanced cancer receiving home PN. 69 From this, it has been suggested that PN should be avoided if the ECOG/WHO PS is 3 or 4. 70 More complex scores and nomograms have been developed to estimate the probability of survival in patients with advanced cancer receiving home PN, e.g. based on Glasgow Prognostic Score, PS, presence of metastatic disease and cancer entity. 65 While these tools may separate groups of patients with similar survival, predictions for individual patients are imprecise.

However, absence of evidence is not identical to evidence of absence of an effect, 71 and a decision to forego the option of intravenous nutrition should not only be based on the lack of high-quality trials. Rather, the decision to initiate PN should be individualised based on the extent of disease, physical and psychological resources of the patient and on a case-by-case risk/benefit assessment (see Table 3).

PN carries the risk of potentially severe complications, including (but not limited to) catheter-related infection, occlusion and thrombosis, derangements of substrate and electrolyte levels, refeeding syndrome, exsiccosis, fluid overload and chronic hepatopathy and osteopathy. 72

PN may be offered to patients who do not tolerate any oral food or those who still tolerate some but inadequate amounts of oral food. The latter has been termed 'supplemental PN', although there is no agreement on the amount of food tolerated to justify this designation. A number of prospective observational studies have reported the effects of PN in patients with advanced cancer suffering from either severe GI obstruction or malnutrition. 66 , 73 , 74 , 75 OS was reported as 57%-75% after 1 month, 34%-67% after 3 months and 12%-34% after 6 months, but this was dependent on the type of patients included. 66 , 73 , 75 Only one of these observational trials reported a small, but not clinically relevant, improvement in QoL. 73 Obling et al. 76 randomised 47 patients with incurable GI cancer to dietary counselling plus either ONSs or supplemental PN. The authors observed improvements in fat-free mass and QoL in favour of the supplemental PN group at 12 weeks but no difference in 6-month survival; however, the statistical analysis was flawed by the very large number of statistical tests carried out. 76 Bouleuc et al. 33 randomised 111 patients with advanced cancer to optimised nutritional care with or without additional supplemental PN for several months; supplemental PN did not improve either QoL or survival but increased severe adverse events. Thus, the potential clinical benefit of PN needs to be balanced against relevant risks (e.g. metabolic derangements, septic complications) and burdens (e.g. connection to an intravenous line for up to 14 hours per day). 33

None of the published trials reported whether patients were aware of their prognosis or the uncertainty about the benefits of PN.

An open question is how to manage the withdrawal of home PN at end of life. Although there has been no formal study on this issue, clinical experience shows that general criteria to withhold home PN when deemed no longer helpful should be considered early at the time when home PN is first offered and thereafter be discussed repeatedly to minimise distress when it is required to phase out PN at end of life.

- In patients with inadequate food intake, nutritional interventions are recommended. In patients with an expected survival of more than several months and in those receiving anticancer therapy, these interventions should be escalated, as required. In other situations, low-risk interventions (e.g. counselling and ONSs) are preferred [II, A].

If safe, the oral route should be the first option for nutritional support. Enteral tube feeding may be used in cases of dysphagia if the small bowel function is preserved. PN should be considered if oral intake and tube feeding are not tolerated or remain inadequate [II, A].

- Nutritional interventions should aim to fulfil energy and nutrient requirements [III, B].

Nutritional interventions should be accompanied by muscle training and efforts to normalise metabolic state (diminish systemic inflammation, alleviate distress) [III, B].

To maintain nutritional status, at least 25-30 kcal/kg BW/day is recommended, adjusting the regimen as required [V, B].

At least 1.2 g protein/kg BW/day should be provided [V, B].

In patients with cachexia, regimens with fat accounting for half of the non-protein calories are recommended [II, B].

- Dietary counselling should be the first choice of nutritional support offered to improve oral intake and possibly weight gain in cachectic or at-risk patients who are able to eat. Dietary counselling should emphasise protein intake, an increased number of meals per day, treatment of nutrition impact symptoms and offering nutritional supplements when necessary. An adequately trained professional should guide this advice [II, B].

ONSs can be supplied as part of dietary counselling to improve energy intake and induce weight gain [II, B].

Patients receiving chemotherapy, radiotherapy or chemoradiotherapy may be offered N3P-ONSs to increase BW, attenuate loss of lean body mass and improve QoL [II, C].

- For patients with head and neck or upper GI cancers, especially those undergoing anticancer treatment, tube feeding to maintain BW or to reduce weight loss is recommended if oral feeding including ONSs is expected to remain inadequate for more than a few days [I, A].

In patients requiring >4 weeks of enteral feeding, PEG rather than NTF is recommended [II, C].

In patients requiring tube feeding, screening for and management of dysphagia is recommended along with encouragement and education to patients regarding how to maintain their swallowing function [II, B].

- Home PN should be offered to patients if their QoL and/or length of survival is expected to be severely compromised by progressive malnutrition. Indicators of a potential benefit are ECOG/WHO PS 0-2, a low level of systemic inflammation (normal levels of serum albumin, modified Glasgow Prognostic Score <2) and the absence of metastatic disease [V, B].

There is insufficient evidence to routinely recommend supplemental PN in hypophagic, malnourished patients receiving chemotherapy to improve QoL and nutrition parameters [V, B].

Current evidence shows that physical exercise is safe and provides benefit in QoL and in muscular and aerobic fitness for people with cancer, both during and after treatment. 77 However, so far, reviews on exercise in cancer cachexia have generally been narrative or based on animal models. A systematic review and meta-analysis of RCTs focusing on exercise training in cachexia found no trials which met the inclusion criteria. 78 An RCT comparing 8 weeks of exercise training with usual care in 231 patients with advanced cancer reported improved physical performance but no effect on

subjective fatigue. 79 However, despite limited robust data, multimodal rehabilitation programmes incorporating exercise and nutritional interventions have been reported to improve many outcomes, most notably those relating to physical endurance and depression scores. 80

While many patients with advanced cancer may drop out of exercise programmes due to progressive disease, when carefully supervised, the intervention appears safe for patients with advanced cancer, even in the hospice setting. 79 , 81 , 82 It is suggested that exercise techniques be chosen based on the individual risk of falls and of skeletal instabilities, and to suspend training when patients experience a fever $>38^{\circ}\text{C}$, infection, platelet count $<20\,000\text{ g/l}$, haemoglobin $<8\text{ g/dl}$ or if they display other contraindications to exercising. 83

Exercise has been hypothesised to attenuate the effects of cancer cachexia by modulating muscle metabolism, insulin sensitivity, anaemia, hypogonadism and systemic inflammation. 84 Physical activity may increase muscle strength and maintain a patient's functional ability, especially when a combination of moderate- to high-intensity resistance and aerobic exercise is undertaken. 84 Exercises of moderate intensity are described as those which fall in between 5-8 metabolic equivalents (METs; a procedure to quantify the energy cost of activities). These include activities that take as much effort as brisk walking (5 km/h), a stationary bike with light effort and home-based exercises. 85 Resistance exercises should alternate between upper and lower limbs, focus on movement quality and use defined sets of repetitions. Aerobic training should be accompanied by continuous or intermittent heart rate monitoring.

- When guided by professional experts, moderate physical exercise is safe in patients with cancer cachexia and is recommended to maintain and improve muscle mass [II, B].

Resistance exercise two to three times per week as well as moderate aerobic (endurance) training should be offered to all patients with cachexia. The exercise prescription should involve a physiotherapist or an adequately trained professional and comprise a structured approach, including mode (aerobic, resistance, flexibility), frequency, intensity and duration as well as defined time points for reassessment [II, B].

Several drugs have been investigated for their potential use to treat or ameliorate the consequences of cancer cachexia. However, only corticosteroids and progestins have consistently shown beneficial effects on appetite and/or BW, though at the expense of substantial side-effects, while for other agents, the data are heterogeneous or disappointing.

The following section presents drugs that are approved for clinical use and have shown some anti-cachexia effect in clinical trials.

Corticosteroids include several agents with variable glucocorticoid, mineralocorticoid and anti-inflammatory potency. Prednisolone, methylprednisolone and dexamethasone are used most frequently. Symptomatic relief appears to be mainly achieved by their potent anti-inflammatory activity. 86 Toxicity is usually minor when used for only a few weeks, whereas during prolonged intake, corticosteroids cause a rapid loss of muscle mass, insulin resistance and increased likelihood of infections, such as candida and stomatitis, contributing to a deterioration of cachectic patients. 87 Corticosteroids are recommended for the control of cancer-related fatigue. 88 Several RCTs investigating the effects of corticosteroids on appetite in patients with advanced cancer have been published. Most trials reported a temporary benefit in appetite and well-being, whereas there were no effects on BW or survival. 7 , 89 The anti-anorectic effect of corticosteroids is transient and often disappears after a few weeks. 90 There are limited data available to recommend one corticosteroid over another.

Medroxyprogesterone acetate and megestrol acetate (MA) have been studied widely to treat weight loss and anorexia in cancer patients. In preclinical models, progestins stimulate appetite and inhibit the synthesis of pro-inflammatory cytokines. A Cochrane review 91 including 23 RCTs on the use of

MA in patients with cancer (median duration of 8 weeks) found a significant improvement in appetite (relative risk 2.57) and weight gain (relative risk 1.55). However, no consistent improvement in QoL was observed and no data on muscle mass or physical function were reported. In the analysed trials, MA was used in doses of 160-800 mg/day and weight improvement appeared higher for doses >160 mg/day, while no dose effect was observed for appetite.

Treatment with MA is associated with an increased risk of thromboembolism, fluid retention, adrenal insufficiency and hypogonadism in male patients. 92 While the aforementioned Cochrane review reported that MA treatment was associated with an increased mortality rate, 91 an update concluded that MA does not increase the rates of adverse events or death. 93

Although progestins have been studied in many RCTs, confirming modest stimulation of appetite, their clinical use is limited because of the significant risk of potentially serious side-effects.

Cannabis sativa is a medical plant containing multiple cannabinoids, including tetrahydrocannabinol (THC). Medical cannabis is available in various formulations, e.g. tablets/capsules, vapouriser or mouth spray.

In patients with cancer cachexia, when studied in small trials and case series, THC appeared to improve appetite and attenuate weight loss. However, larger randomised trials comparing THC with either MA 94 or placebo 95 could not detect a significant effect on appetite or QoL; in these trials, toxicity was low. In a small, placebo-controlled, 8-week RCT in 47 anorectic patients with advanced non-small-cell lung cancer, the synthetic THC derivative, nabilone, resulted in low toxicity but no significant effects on appetite or QoL. 96 Current safety data for medical cannabis in cancer cachexia is based on only a few trials that likely under-dosed patients and so safety concerns remain.

In cancer patients, hypogonadism is related to advanced cancer status, weight loss and, most likely, the use of opioid therapy. Anabolic-androgenic steroids have been shown to ameliorate loss of muscle mass and strength in patients with wasting associated with acquired immune deficiency syndrome. The use of androgens has not been studied extensively in patients with cancer cachexia. In an RCT of 37 lung cancer patients, the analogue nandrolone did not improve BW compared with placebo. 97 In a three-armed RCT including 496 patients with cachexia, fluoxymesterone 10 mg b.i.d. was significantly inferior to MA 800 mg/day in terms of appetite improvement. 98

Olanzapine is an atypical antipsychotic drug acting on multiple receptors, including dopamine and serotonin receptors, both of which are potentially relevant in cachexia. 99 In clinical use, olanzapine causes more weight gain than other antipsychotic drugs. 100 In a single arm, dose escalation study in 39 weight-losing patients with advanced cancer, olanzapine could not attenuate weight loss. 101 However, in a trial randomising 80 patients with advanced cancer to receive MA or MA and olanzapine, the combination arm yielded significant improvements in appetite and BW. 99 In a recent RCT, olanzapine significantly reduced non-chemotherapy-induced nausea in 30 patients with advanced cancer compared with placebo. 102 Thus, olanzapine may be considered for treating chronic nausea in patients with advanced cancer.

Non-steroidal anti-inflammatory drugs (NSAIDs) block the cyclooxygenase pathways and reduce inflammation by inhibiting prostaglandin production. NSAIDs have been studied to reduce the catabolic drive of systemic inflammation in patients with advanced cancer and cachexia. In a systematic review including six controlled trials and seven observational trials, 103 11 of these trials reported an increase or stabilisation of BW or lean body mass with few side-effects reported. The cumulative evidence, however, was weak due to the low methodological quality of the analysed trials. Thus, in cachectic patients requiring pain control, NSAIDs could be considered with the potential additional benefit of improving BW.

Metoclopramide and domperidone are widely used to treat early satiety and chronic nausea 104 as well as dyspepsia syndrome and gastroparesis. 105 However, no large RCT has investigated the role of prokinetic agents in cachexia. While one RCT in patients with advanced cancer showed that metoclopramide may improve nausea but not appetite, 106 there are no similar studies with domperidone.

Metoclopramide and domperidone can cause serious, mainly neurological, side-effects, e.g. tardive dyskinesia, spasms, depression, dizziness and urinary retention. 107

Anamorelin has recently been approved in Japan for cancer cachexia in patients with non-small-cell lung cancer, gastric cancer, pancreatic cancer and colorectal cancer, but it is not approved in Europe based on findings from the ROMANO studies which showed a more modest improvement in lean body mass compared with that seen in the Japanese trials.

Published trials investigating potential synergies among pharmacological agents like progestins, antioxidants, L-carnitine, thalidomide, n-3 fatty acids and NSAIDs were unsuccessful or unreliable due to methodological deficiencies. 108 , 109

- Corticosteroids may be used to increase appetite for a short period of up to 2-3 weeks. Effects on appetite usually disappear with longer treatment [I, B].

Progestins may be used to increase appetite and BW, but not muscle mass, QoL or physical function in patients with cancer cachexia [I, B]. The risk of serious side-effects, including thromboembolic events, must be considered.

There is insufficient evidence to support the use of medical cannabis or its derivatives to alleviate anorexia or early satiety in patients with cancer cachexia [II, C].

As there is evidence of no beneficial effect in terms of improvement in muscle mass, androgens are not recommended [II, D].

There is moderate evidence to suggest considering the use of olanzapine to treat appetite and nausea in patients with advanced cancer [II, B].

There is insufficient evidence to recommend the use of NSAIDs alone to treat cancer cachexia [III, C].

There is insufficient evidence to recommend the use of metoclopramide or domperidone alone to treat cancer cachexia [II, C].

There is insufficient evidence to recommend specific combination regimens due to the lack of evidence from large, well-designed, randomised trials [II, C].

In the presence of cachexia-related symptoms such as anorexia and fatigue, patients and their families experience stressful changes in eating habits and challenging social interactions. 110 , 111 Patients report wanting and trying to eat but being unable to do so, while family members often misunderstand the complex and powerful derangements responsible for anorexia and food aversion in cachexia and pressure their relative to eat, thus increasing tension and conflict in the patient–family unit. 112 , 113 In addition, continued loss of weight and function alters the patient's appearance with consequences on their self-image and self-esteem. 113

Early identification of psychosocial distress and the impact of cachexia allows for timely interventions to manage distressing symptoms and improve QoL. 114

Focus groups and semi-structured interviews with 34 Irish health care professionals revealed that doctors, nurses and dieticians tend to avoid the problem of cancer cachexia because of difficulties in communicating its complex and often irreversible nature and negative prognosis, and for fear of lowering the patient's hope. 115 A missed acknowledgement, however, has made family members feel misinformed and isolated. 116 Poor communication by health care professionals may weaken the confidence of patients and families in their knowledge and understanding of cachexia; thus, transparent information is clearly preferred. 116 A large survey (response rate 76%) of 702 bereaved family members of cancer patients in Japan suggested that health care professionals may relieve psychological and emotional distress by explaining the mechanisms of cancer cachexia as simply as possible. 117

Tailored information about the role of nutritional support according to the stage of cachexia (see Figure 3) is fundamental to achieving agreement between health care professionals, patients and families on treatment goals. A systematic review including 19 studies investigating eating-related distress in patients with cachexia found that the main causes of negative psychosocial effects are a lack of knowledge regarding the nature of cancer cachexia and unsuccessful attempts to increase BW. A structured and informative intervention prevents families from feeling overwhelmed by their loved one's disease and alone in managing weight and eating problems. 118

These findings suggest that patients and their families need honest and problem-centred communication tailored to the disease stage.

The aim of psychosocial interventions is to reduce the emotional burden associated with cancer cachexia by empowering patients and families to cope with the dysfunctions and derangements of cachexia, thus improving QoL. 118 , 119 , 120 Health care professionals can adopt different strategies (e.g. DVDs, stories, open questions) to help patients and families to share their perspectives about food-related issues. 120

A small, randomised, exploratory trial evaluating psychosocial intervention on weight and eating-related distress in 50 patients with advanced cancer found that treated patients reported lower levels of distress compared with the control group. 118 Qualitative analysis suggested that psychosocial intervention was helpful for carers as it provided information, reassurance and support for self-management. 119 In a small, mixed-methods, qualitative research study, a family-centred psychosocial intervention was developed and delivered by a single nurse researcher to help patients with advanced cancer and their families/caregivers to cope with the patient's involuntary weight loss and worsening appetite. The intervention was delivered during face-to-face consultations and 15 out of 16 patient–caregiver dyads reported benefits. 120

- Health care professionals should routinely assess patients and their families to permit timely identification of any psychosocial distress [V, B].

Health care professionals should provide tailored information according to the stage of cachexia and empower patients and their families to understand its nature, course and biological mechanisms, and to acknowledge its negative effects (e.g. weight loss, reduced appetite, early satiety), thereby promoting greater awareness about the clinical condition and the need for early multidisciplinary intervention [IV, B].

Psychosocial interventions should be considered as early as possible in cachexia management. They should be conducted by trained health care professionals and aim to help patients and their families to cope with involuntary weight loss and to strengthen the dyadic coping resources [III, B].

Multimodal interventions against cancer cachexia have been advocated for more than a decade based on the complex underlying pathophysiology [see Section 2 (text and Supplementary Figure S2) of the Supplementary Material , available at <https://doi.org/10.1016/j.esmooop.2021.100092>] and the wealth of contributing factors impacting on BW, muscle mass, food intake and physical

function. 121 Components of such multimodal support may target calorific intake, physical activity, psychosocial and spiritual functions, as well as key factors in cachexia pathophysiology, such as inflammation. The concept of using synergies of supportive interventions has been described to achieve 'anabolic competence'. 122 Examples of multimodal care in daily clinical practice have been assembled by Maddocks et al. 123 However, so far, few trials combining separate treatment modalities have been reported; ongoing investigations primarily focus on simultaneously targeting nutritional support, muscle training and anti-inflammatory concepts. Importantly, in healthy subjects, bouts of physical exercise significantly prolong the increase in muscle protein synthesis induced by feeding. 124

The randomised, 6-week, MENAC pilot trial compared a multimodal combination of NSAIDs, nutritional advice, oral supplements enriched in eicosapentaenoic acid and physical exercise to standard treatment in 46 patients with solid tumours starting chemotherapy. 82 This trial showed that the intervention improved BW and is now being followed by a phase III trial recruiting patients with lung and pancreatic cancer. Another small trial, randomising 58 patients with advanced cancer to usual care or 12 weeks of an exercise training programme combined with repeated nutritional counselling, showed a significant increase in protein intake and a decrease in nausea and vomiting. 125 Recently, a large RCT including 328 patients with previously untreated metastatic oesophago-gastric cancer received either standard care or additional nutritional and psychological interventions; combined-modality support resulted in improved OS in the intention-to-treat analysis. 126

- In patients with cachexia, combining nutritional support with exercise training and psychological support is proposed [II, B]. Anti-inflammatory interventions should also be considered [V, C].

Critical points for cachexia care are to implement screening, assessment and treatment in routine cancer care. Initiating and maintaining these efforts, including a quality control process, requires support by the institutional leadership. Evidence for the effectiveness of cachexia clinics is scarce due to a lack of RCTs. 127 Extrapolation from pain interventions 128 or specialised palliative care 129 suggests its potential effectiveness. Typically, a registered dietician, physiotherapist, palliative care nurse, psychologist and a palliative/supportive/rehabilitative care specialist—who ideally would also be a medical oncologist 130 —could build the 'inner circle' of a cachexia clinic or team (Figure 6). A close integration of these professionals within the cancer clinic (e.g. case discussions, tumour boards, clinical rounds, education, clinical trials), as well as access to specialised professionals such as gastroenterologists (e.g. for vent, stent, gastrostomy, jejunostomy), head and neck specialists, logopaedic experts and invasive pain specialists, is highly recommended. Figure 6 Responsibilities and interactions of members of the multimodal care team.

Solid line arrows depict responsibilities. Dashed line arrows depict interactions. Further cooperation (e.g. with gastroenterologists, surgeons, head and neck specialists) will frequently be necessary.

- Screening for cachexia should be integrated into routine cancer care, supported by accountable professionals and linked to immediate access to cachexia care interventions [V, B].

Cachexia care should be delivered utilising a combination of nutrition, physical activity, psychological, oncological, palliative/supportive/rehabilitative care and oncologist competencies [V, B].

This CPG was developed in accordance with the ESMO standard operating procedures for CPG development (<https://www.esmo.org/guidelines/esmo-guidelines-methodology>). The relevant literature has been selected by the expert authors. Levels of evidence and grades of recommendation have been applied using the system shown in Supplementary Table S3 , available at <https://doi.org/10.1016/j.esmoop.2021.100092> . 131 Statements without grading were considered justified standard clinical practice by the experts.

Fearon K. Arends J. Baracos V. Understanding the mechanisms and treatment options in cancer cachexia *Nat Rev Clin Oncol* 10 2 2013 90 99 23207794 10.1038/nrclinonc.2012.209 2
 Schcolnik-Cabrera A. Chávez-Blanco A. Domínguez-Gómez G. Understanding tumor anabolism and patient catabolism in cancer-associated cachexia *Am J Cancer Res* 7 5 2017 1107 1135 28560061 PMC5446478 3 Mannion E. Gilmartin J.J. Donnellan P. Effect of chemotherapy on quality of life in patients with non-small cell lung cancer *Support Care Cancer* 22 5 2014 1417 1428 24563068 10.1007/s00520-014-2148-9 4 Prigerson H.G. Bao Y. Shah M.A. Chemotherapy use, performance status, and quality of life at the end of life *JAMA Oncol* 1 6 2015 778 784 26203912 10.1001/jamaoncol.2015.2378 PMC4828728 5 Roeland E.J. Bohlke K. Baracos V.E. Management of cancer cachexia: ASCO guideline *J Clin Oncol* 38 21 2020 2438 2453 32432946 10.1200/JCO.20.00611 6 Fearon K. Strasser F. Anker S.D. Definition and classification of cancer cachexia: an international consensus *Lancet Oncol* 12 5 2011 489 495 21296615 10.1016/S1470-2045(10)70218-7 7 Arends J. Bachmann P. Baracos V. ESPEN guidelines on nutrition in cancer patients *Clin Nutr* 36 1 2017 11 48 27637832 10.1016/j.clnu.2016.07.015 8 Cederholm T. Jensen G.L. Correia M. GLIM criteria for the diagnosis of malnutrition – a consensus report from the global clinical nutrition community *Clin Nutr* 38 1 2019 1 9 30181091 10.1016/j.clnu.2018.08.002 9 Cahill G.F. Jr. Starvation in man *N Engl J Med* 282 12 1970 668 675 4915800 10.1056/NEJM197003192821209 10 Arends J. Mangelernährung bei Tumorpacienten *Onkologe* 14 2008 9 14 11 Jensen G.L. Mirtallo J. Compher C. Adult starvation and disease-related malnutrition: a proposal for etiology-based diagnosis in the clinical practice setting from the International Consensus Guideline Committee *Clin Nutr* 29 2 2010 151 153 20071059 10.1016/j.clnu.2009.11.010 12 Coussens L.M. Werb Z. Inflammation and cancer *Nature* 420 6917 2002 860 867 12490959 10.1038/nature01322 PMC2803035 13 Baracos V.E. Martin L. Korc M. Cancer-associated cachexia *Nat Rev Dis Primers* 4 2018 17105 29345251 10.1038/nrdp.2017.105 14 Straub R.H. Evolutionary medicine and chronic inflammatory state – known and new concepts in pathophysiology *J Mol Med (Berl)* 90 5 2012 523 534 22271169 10.1007/s00109-012-0861-8 PMC3354326 15 McMillan D.C. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer *Cancer Treat Rev* 39 5 2013 534 540 22995477 10.1016/j.ctrv.2012.08.003 16 Fearon K.C. Glass D.J. Guttridge D.C. Cancer cachexia: mediators, signaling, and metabolic pathways *Cell Metab* 16 2 2012 153 166 22795476 10.1016/j.cmet.2012.06.011 17 Cruz-Jentoft A.J. Bahat G. Bauer J. Sarcopenia: revised European consensus on definition and diagnosis *Age Ageing* 48 1 2019 16 31 30312372 10.1093/ageing/afy169 PMC6322506 18 Bozzetti F. Chemotherapy-induced sarcopenia *Curr Treat Options Oncol* 21 1 2020 7 32002684 10.1007/s11864-019-0691-9 19 Prado C.M. Lieffers J.R. McCargar L.J. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study *Lancet Oncol* 9 7 2008 629 635 18539529 10.1016/S1470-2045(08)70153-0 20 Caillet P. Liuu E. Raynaud Simon A. Association between cachexia, chemotherapy and outcomes in older cancer patients: a systematic review *Clin Nutr* 36 6 2017 1473 1482 28017447 10.1016/j.clnu.2016.12.003 21 van Bokhorst-de van der Schueren M.A. Guaitoli P.R. Jansma E.P. Nutrition screening tools: does one size fit all? A systematic review of screening tools for the hospital setting *Clin Nutr* 33 1 2014 39 58 23688831 10.1016/j.clnu.2013.04.008 22 Isenring E. Elia M. Which screening method is appropriate for older cancer patients at risk for malnutrition? *Nutrition* 31 4 2015 594 597 25770324 10.1016/j.nut.2014.12.027 23 Omlin A. Blum D. Wierecky J. Nutrition impact symptoms in advanced cancer patients: frequency and specific interventions, a case-control study *J Cachexia Sarcopenia Muscle* 4 1 2013 55 61 23307589 10.1007/s13539-012-0099-x PMC3581613 24 Krishnan M. Temel J.S. Wright A.A. Predicting life expectancy in patients with advanced incurable cancer: a review *J Support Oncol* 11 2 2013 68 74 23967494 10.12788/j.suonc.0004 25 Hui D. Paiva C.E. Del Fabbro E.G. Prognostication in advanced cancer: update and directions for future research *Support Care Cancer* 27 6 2019 1973 1984 30863893 10.1007/s00520-019-04727-y PMC6500464 26 Simmons C.P.L. McMillan D.C. McWilliams K. Prognostic tools in patients with advanced cancer: a systematic review *J Pain Symptom Manage* 53 5 2017 962 970.e10 28062344 10.1016/j.jpainsymman.2016.12.330 27 Arends J. Struggling with nutrition in patients with advanced cancer: nutrition and nourishment-focusing on metabolism and supportive care *Ann Oncol* 29 suppl_2 2018 ii27 ii34 10.1093/annonc/mdy093 29741571 28 Dev R. Bruera E. Dalal S. Insulin resistance and body composition in cancer patients *Ann Oncol* 29 suppl_2 2018 ii18 ii26 10.1093/annonc/mdx815 29506229 29 Haran P.H. Rivas D.A. Fielding R.A. Role and potential

mechanisms of anabolic resistance in sarcopenia J Cachexia Sarcopenia Muscle 3 3 2012 157 162 22589021 10.1007/s13539-012-0068-4 PMC3424190 30 Baldwin C. Spiro A. Ahern R. Oral nutritional interventions in malnourished patients with cancer: a systematic review and meta-analysis J Natl Cancer Inst 104 5 2012 371 385 22345712 10.1093/jnci/djr556 31 Bourdel-Marchasson I. Blanc-Bisson C. Doussau A. Nutritional advice in older patients at risk of malnutrition during treatment for chemotherapy: a two-year randomized controlled trial PLoS One 9 9 2014 e108687 25265392 10.1371/journal.pone.0108687 PMC4181649 32 de van der Schueren M.A.E. Laviano A. Blanchard H. Systematic review and meta-analysis of the evidence for oral nutritional intervention on nutritional and clinical outcomes during chemo(radio)therapy: current evidence and guidance for design of future trials Ann Oncol 29 5 2018 1141 1153 29788170 10.1093/annonc/mdy114 PMC5961292 33 Bouleuc C. Anota A. Cornet C. Impact on health-related quality of life of parenteral nutrition for patients with advanced cancer cachexia: results from a randomized controlled trial Oncologist 25 5 2020 e843 e851 32212354 10.1634/theoncologist.2019-0856 PMC7216468 34 Oh S.Y. Jun H.J. Park S.J. A randomized phase II study to assess the effectiveness of fluid therapy or intensive nutritional support on survival in patients with advanced cancer who cannot be nourished via enteral route J Palliat Med 17 11 2014 1266 1270 24984081 10.1089/jpm.2014.0082 35 Purcell S.A. Elliott S.A. Walter P.J. Total energy expenditure in patients with colorectal cancer: associations with body composition, physical activity, and energy recommendations Am J Clin Nutr 110 2 2019 367 376 31225583 10.1093/ajcn/nqz112 PMC6669058 36 Bozzetti F. Bozzetti V. Is the intravenous supplementation of amino acid to cancer patients adequate? A critical appraisal of literature Clin Nutr 32 1 2013 142 146 23218120 10.1016/j.clnu.2012.10.017 37 Winter A. MacAdams J. Chevalier S. Normal protein anabolic response to hyperaminoacidemia in insulin-resistant patients with lung cancer cachexia Clin Nutr 31 5 2012 765 773 22647419 10.1016/j.clnu.2012.05.003 38 Wolfe R.R. The 2017 Sir David P. Cuthbertson lecture. Amino acids and muscle protein metabolism in critical care Clin Nutr 37 4 2018 1093 1100 29291898 10.1016/j.clnu.2017.12.010 39 Cao D.X. Wu G.H. Zhang B. Resting energy expenditure and body composition in patients with newly detected cancer Clin Nutr 29 1 2010 72 77 19647909 10.1016/j.clnu.2009.07.001 40 Körber J. Pricelius S. Heidrich M. Increased lipid utilization in weight losing and weight stable cancer patients with normal body weight Eur J Clin Nutr 53 9 1999 740 745 10509772 10.1038/sj.ejcn.1600843 41 Fearon K.C. Borland W. Preston T. Cancer cachexia: influence of systemic ketosis on substrate levels and nitrogen metabolism Am J Clin Nutr 47 1 1988 42 48 3122552 10.1093/ajcn/47.1.42 42 Breikreutz R. Tesdal K. Jentschura D. Effects of a high-fat diet on body composition in cancer patients receiving chemotherapy: a randomized controlled study Wien Klin Wochenschr 117 19-20 2005 685 692 16416368 10.1007/s00508-005-0455-3 43 Garg S. Yoo J. Winquist E. Nutritional support for head and neck cancer patients receiving radiotherapy: a systematic review Support Care Cancer 18 6 2010 667 677 19582484 10.1007/s00520-009-0686-3 44 Langius J.A. Zandbergen M.C. Eerenstein S.E. Effect of nutritional interventions on nutritional status, quality of life and mortality in patients with head and neck cancer receiving (chemo)radiotherapy: a systematic review Clin Nutr 32 5 2013 671 678 23845384 10.1016/j.clnu.2013.06.012 45 Balstad T.R. Solheim T.S. Strasser F. Dietary treatment of weight loss in patients with advanced cancer and cachexia: a systematic literature review Crit Rev Oncol Hematol 91 2 2014 210 221 24703549 10.1016/j.critrevonc.2014.02.005 46 Lee J.L.C. Leong L.P. Lim S.L. Nutrition intervention approaches to reduce malnutrition in oncology patients: a systematic review Support Care Cancer 24 1 2016 469 480 26404858 10.1007/s00520-015-2958-4 47 Blackwood H.A. Hall C.C. Balstad T.R. A systematic review examining nutrition support interventions in patients with incurable cancer Support Care Cancer 28 4 2020 1877 1889 31359182 10.1007/s00520-019-04999-4 48 de Aguiar Pastore Silva J. Emilia de Souza Fabre M. Waitzberg D.L. Omega-3 supplements for patients in chemotherapy and/or radiotherapy: a systematic review Clin Nutr 34 3 2015 359 366 25907586 10.1016/j.clnu.2014.11.005 49 Cereda E. Cappello S. Colombo S. Nutritional counseling with or without systematic use of oral nutritional supplements in head and neck cancer patients undergoing radiotherapy Radiother Oncol 126 1 2018 81 88 29111172 10.1016/j.radonc.2017.10.015 50 van der Meij B.S. van Bokhorst-de van der Schueren M.A. Langius J.A. n-3 PUFAs in cancer, surgery, and critical care: a systematic review on clinical effects, incorporation, and washout of oral or enteral compared with parenteral supplementation Am J Clin Nutr 94 5 2011 1248 1265 21940600 10.3945/ajcn.110.007377 51 Dewey A. Baughan C. Dean T. Eicosapentaenoic acid (EPA, an omega-3 fatty acid from fish oils) for the treatment of cancer cachexia Cochrane Database Syst Rev

2007 1 2007 Cd004597 10.1002/14651858.CD004597.pub2 PMC6464930 17253515 52 Bossola M. Nutritional interventions in head and neck cancer patients undergoing chemoradiotherapy: a narrative review *Nutrients* 7 1 2015 265 276 25569622 10.3390/nu7010265 PMC4303838 53 Blumenstein I. Shastri Y.M. Stein J. Gastroenteric tube feeding: techniques, problems and solutions *World J Gastroenterol* 20 26 2014 8505 8524 25024606 10.3748/wjg.v20.i26.8505 PMC4093701 54 Altintas N.D. Aydin K. Türkoğlu M.A. Effect of enteral versus parenteral nutrition on outcome of medical patients requiring mechanical ventilation *Nutr Clin Pract* 26 3 2011 322 329 21531737 10.1177/0884533611405790 55 Chow R. Bruera E. Arends J. Enteral and parenteral nutrition in cancer patients, a comparison of complication rates: an updated systematic review and (cumulative) meta-analysis *Support Care Cancer* 28 3 2020 979 1010 31813021 10.1007/s00520-019-05145-w 56 Scolapio J.S. Picco M.F. Tarrosa V.B. Enteral versus parenteral nutrition: the patient's preference *JPEN J Parenter Enteral Nutr* 26 4 2002 248 250 12090690 10.1177/0148607102026004248 57 King P.C. Barrimore S.E. Pulle R.C. "I wouldn't ever want it": a qualitative evaluation of patient and caregiver perceptions toward enteral tube feeding in hip fracture inpatients *JPEN J Parenter Enteral Nutr* 43 4 2019 526 533 30199088 10.1002/jpen.1444 58 Bozzetti F. Nutritional support of the oncology patient *Crit Rev Oncol Hematol* 87 2 2013 172 200 23746998 10.1016/j.critrevonc.2013.03.006 59 Canadian Agency for Drugs and Technologies in Health Nasogastric feeding tubes versus percutaneous endoscopic gastrostomy for patients with head or neck cancer: a review of clinical effectiveness and guidelines Available at <https://www.ncbi.nlm.nih.gov/books/NBK253809/> 2014 Accessed September 7, 2020 25411678 60 Corry J. Poon W. McPhee N. Randomized study of percutaneous endoscopic gastrostomy versus nasogastric tubes for enteral feeding in head and neck cancer patients treated with (chemo)radiation *J Med Imaging Radiat Oncol* 52 5 2008 503 510 19032398 10.1111/j.1440-1673.2008.02003.x 61 Sadasivan A. Faizal B. Kumar M. Nasogastric and percutaneous endoscopic gastrostomy tube use in advanced head and neck cancer patients: a comparative study *J Pain Palliat Care Pharmacother* 26 3 2012 226 232 22973911 10.3109/15360288.2012.702199 62 Zhang Z. Zhu Y. Ling Y. Comparative effects of different enteral feeding methods in head and neck cancer patients receiving radiotherapy or chemoradiotherapy: a network meta-analysis *Onco Targets Ther* 9 2016 2897 2909 27274283 10.2147/OTT.S101983 PMC4876095 63 Wang J. Liu M. Liu C. Percutaneous endoscopic gastrostomy versus nasogastric tube feeding for patients with head and neck cancer: a systematic review *J Radiat Res* 55 3 2014 559 567 24453356 10.1093/jrr/rrt144 PMC4014167 64 Bozzetti F. Santarpia L. Pironi L. The prognosis of incurable cachectic cancer patients on home parenteral nutrition: a multi-centre observational study with prospective follow-up of 414 patients *Ann Oncol* 25 2 2014 487 493 24406425 10.1093/annonc/mdt549 65 Bozzetti F. Cotogni P. Lo Vullo S. Development and validation of a nomogram to predict survival in incurable cachectic cancer patients on home parenteral nutrition *Ann Oncol* 26 11 2015 2335 2340 26347103 10.1093/annonc/mdv365 66 Cotogni P. De Carli L. Passera R. Longitudinal study of quality of life in advanced cancer patients on home parenteral nutrition *Cancer Med* 6 7 2017 1799 1806 28557362 10.1002/cam4.1111 PMC5504329 67 Sowerbutts A.M. Lal S. Sremanakova J. Home parenteral nutrition for people with inoperable malignant bowel obstruction *Cochrane Database Syst Rev* 8 8 2018 Cd012812 30095168 10.1002/14651858.CD012812.pub2 PMC6513201 68 Tobberup R. Thoresen L. Falkmer U.G. Effects of current parenteral nutrition treatment on health-related quality of life, physical function, nutritional status, survival and adverse events exclusively in patients with advanced cancer: a systematic literature review *Crit Rev Oncol Hematol* 139 2019 96 107 31150954 10.1016/j.critrevonc.2019.04.014 69 Keane N. Fragkos K.C. Patel P.S. Performance status, prognostic scoring, and parenteral nutrition requirements predict survival in patients with advanced cancer receiving home parenteral nutrition *Nutr Cancer* 70 1 2018 73 82 29111787 10.1080/01635581.2018.1380206 70 Bozzetti F. Cozzaglio L. Biganzoli E. Quality of life and length of survival in advanced cancer patients on home parenteral nutrition *Clin Nutr* 21 4 2002 281 288 12135587 10.1054/clnu.2002.0560 71 Altman D.G. Bland J.M. Absence of evidence is not evidence of absence *BMJ* 311 7003 1995 485 7647644 10.1136/bmj.311.7003.485 PMC2550545 72 Pironi L. Arends J. Bozzetti F. ESPEN guidelines on chronic intestinal failure in adults *Clin Nutr* 35 2 2016 247 307 26944585 10.1016/j.clnu.2016.01.020 73 Culine S. Chambrier C. Tadmouri A. Home parenteral nutrition improves quality of life and nutritional status in patients with cancer: a French observational multicentre study *Support Care Cancer* 22 7 2014 1867 1874 24557011 10.1007/s00520-014-2164-9 74 Girke J. Seipt C. Markowski A. Quality of life and nutrition condition

of patients improve under home parenteral nutrition: an exploratory study *Nutr Clin Pract* 31 5 2016 659 665 27165116 10.1177/0884533616637949 75 Vashi P.G. Dahlk S. Popiel B. A longitudinal study investigating quality of life and nutritional outcomes in advanced cancer patients receiving home parenteral nutrition *BMC Cancer* 14 2014 593 25128023 10.1186/1471-2407-14-593 PMC4141117 76 Obling S.R. Wilson B.V. Pfeiffer P. Home parenteral nutrition increases fat free mass in patients with incurable gastrointestinal cancer. Results of a randomized controlled trial *Clin Nutr* 38 1 2019 182 190 29305245 10.1016/j.clnu.2017.12.011 77 Segal R. Zwaal C. Green E. Exercise for people with cancer: a systematic review *Curr Oncol* 24 4 2017 e290 e315 28874900 10.3747/co.24.3619 PMC5576469 78 Grande A.J. Silva V. Maddocks M. Exercise for cancer cachexia in adults: executive summary of a Cochrane Collaboration systematic review *J Cachexia Sarcopenia Muscle* 6 3 2015 208 211 26401466 10.1002/jcsm.12055 PMC4575551 79 Oldervoll L.M. Loge J.H. Lydersen S. Physical exercise for cancer patients with advanced disease: a randomized controlled trial *Oncologist* 16 11 2011 1649 1657 21948693 10.1634/theoncologist.2011-0133 PMC3233301 80 Hall C.C. Cook J. Maddocks M. Combined exercise and nutritional rehabilitation in outpatients with incurable cancer: a systematic review *Support Care Cancer* 27 7 2019 2371 2384 30944994 10.1007/s00520-019-04749-6 PMC6541700 81 Malcolm L. Mein G. Jones A. Strength in numbers: patient experiences of group exercise within hospice palliative care *BMC Palliat Care* 15 1 2016 97 27964735 10.1186/s12904-016-0173-9 PMC5155388 82 Solheim T.S. Laird B.J.A. Balstad T.R. A randomized phase II feasibility trial of a multimodal intervention for the management of cachexia in lung and pancreatic cancer *J Cachexia Sarcopenia Muscle* 8 5 2017 778 788 28614627 10.1002/jcsm.12201 PMC5659068 83 Oechsle K. Aslan Z. Suesse Y. Multimodal exercise training during myeloablative chemotherapy: a prospective randomized pilot trial *Support Care Cancer* 22 1 2014 63 69 23989498 10.1007/s00520-013-1927-z 84 Hardee J.P. Counts B.R. Carson J.A. Understanding the role of exercise in cancer cachexia therapy *Am J Lifestyle Med* 13 1 2019 46 60 30627079 10.1177/1559827617725283 PMC6311610 85 Jetté M. Sidney K. Blümchen G. Metabolic equivalents (METs) in exercise testing, exercise prescription, and evaluation of functional capacity *Clin Cardiol* 13 8 1990 555 565 2204507 10.1002/clc.4960130809 86 Coutinho A.E. Chapman K.E. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights *Mol Cell Endocrinol* 335 1 2011 2 13 20398732 10.1016/j.mce.2010.04.005 PMC3047790 87 Schakman O. Kalista S. Barbé C. Glucocorticoid-induced skeletal muscle atrophy *Int J Biochem Cell Biol* 45 10 2013 2163 2172 23806868 10.1016/j.biocel.2013.05.036 88 Fabi A. Bhargava R. Fatigoni S. Cancer-related fatigue: ESMO Clinical Practice Guidelines for diagnosis and treatment *Ann Oncol* 31 6 2020 713 723 32173483 10.1016/j.annonc.2020.02.016 89 Yavuzsen T. Davis M.P. Walsh D. Systematic review of the treatment of cancer-associated anorexia and weight loss *J Clin Oncol* 23 33 2005 8500 8511 16293879 10.1200/JCO.2005.01.8010 90 Moertel C.G. Schutt A.J. Reitemeier R.J. Corticosteroid therapy of preterminal gastrointestinal cancer *Cancer* 33 6 1974 1607 1609 4135151 10.1002/1097-0142(197406)33:6<1607::aid-cnrcr2820330620>3.0.co;2-v 91 Ruiz Garcia V. López-Briz E. Carbonell Sanchis R. Megestrol acetate for treatment of anorexia-cachexia syndrome *Cochrane Database Syst Rev* 2013 3 2013 Cd004310 10.1002/14651858.CD004310.pub3 PMC6418472 23543530 92 Dev R. Del Fabbro E. Bruera E. Association between megestrol acetate treatment and symptomatic adrenal insufficiency with hypogonadism in male patients with cancer *Cancer* 110 6 2007 1173 1177 17647248 10.1002/cncr.22924 93 Ruiz-García V. López-Briz E. Carbonell-Sanchis R. Megestrol acetate for cachexia-anorexia syndrome. A systematic review *J Cachexia Sarcopenia Muscle* 9 3 2018 444 452 29542279 10.1002/jcsm.12292 PMC5989756 94 Jatoi A. Windschitl H.E. Loprinzi C.L. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study *J Clin Oncol* 20 2 2002 567 573 11786587 10.1200/JCO.2002.20.2.567 95 Strasser F. Luftner D. Possinger K. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group *J Clin Oncol* 24 21 2006 3394 3400 16849753 10.1200/JCO.2005.05.1847 96 Turcott J.G. Del Rocío Guillén Núñez M. Flores-Estrada D. The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: a randomized, double-blind clinical trial *Support Care Cancer* 26 9 2018 3029 3038 29550881 10.1007/s00520-018-4154-9 97 Chlebowski R.T. Herrold J. Ali I. Influence of nandrolone decanoate on weight loss in advanced non-small cell lung cancer *Cancer* 58 1 1986 183 186

3518910 10.1002/1097-0142(19860701)58:1<183::aid-cnrcr2820580131>3.0.co;2-3 98 Loprinzi C.L. Kugler J.W. Sloan J.A. Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia *J Clin Oncol* 17 10 1999 3299 3306 10506633 10.1200/JCO.1999.17.10.3299 99 Navari R.M. Brenner M.C. Treatment of cancer-related anorexia with olanzapine and megestrol acetate: a randomized trial *Support Care Cancer* 18 8 2010 951 956 19756773 10.1007/s00520-009-0739-7 100 Parsons B. Allison D.B. Loebel A. Weight effects associated with antipsychotics: a comprehensive database analysis *Schizophr Res* 110 1-3 2009 103 110 19321312 10.1016/j.schres.2008.09.025 101 Naing A. Dalal S. Abdelrahim M. Olanzapine for cachexia in patients with advanced cancer: an exploratory study of effects on weight and metabolic cytokines *Support Care Cancer* 23 9 2015 2649 2654 25680763 10.1007/s00520-015-2625-9 102 Navari R.M. Pywell C.M. Le-Rademacher J.G. Olanzapine for the treatment of advanced cancer-related chronic nausea and/or vomiting: a randomized pilot trial *JAMA Oncol* 6 6 2020 895 899 32379269 10.1001/jamaoncol.2020.1052 PMC7206532 103 Solheim T.S. Fearon K.C. Blum D. Non-steroidal anti-inflammatory treatment in cancer cachexia: a systematic literature review *Acta Oncol* 52 1 2013 6 17 23020528 10.3109/0284186X.2012.724536 104 Del Fabbro E. Hui D. Dalal S. Clinical outcomes and contributors to weight loss in a cancer cachexia clinic *J Palliat Med* 14 9 2011 1004 1008 21793729 10.1089/jpm.2011.0098 PMC3166181 105 Camilleri M. Parkman H.P. Shafi M.A. Clinical guideline: management of gastroparesis *Am J Gastroenterol* 108 1 2013 18 37 quiz 38 23147521 10.1038/ajg.2012.373 PMC3722580 106 Bruera E. Belzile M. Neumann C. A double-blind, crossover study of controlled-release metoclopramide and placebo for the chronic nausea and dyspepsia of advanced cancer *J Pain Symptom Manage* 19 6 2000 427 435 10908823 10.1016/S0885-3924(00)00138-X 107 European Medicine Agency Metoclopramide-containing medicines Available at: <https://www.ema.europa.eu/en/medicines/human/referrals/metoclopramide-containing-medicines> Accessed March 31, 2021 108 Mantovani G. Macciò A. Madeddu C. Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia *Oncologist* 15 2 2010 200 211 20156909 10.1634/theoncologist.2009-0153 PMC3227938 109 Mantovani G. Madeddu C. Cancer cachexia: medical management *Support Care Cancer* 18 1 2010 1 9 19688225 10.1007/s00520-009-0722-3 110 Oberholzer R. Hopkinson J.B. Baumann K. Psychosocial effects of cancer cachexia: a systematic literature search and qualitative analysis *J Pain Symptom Manage* 46 1 2013 77 95 23159682 10.1016/j.jpainsymman.2012.06.020 111 Strasser F. Binswanger J. Cerny T. Fighting a losing battle: eating-related distress of men with advanced cancer and their female partners. A mixed-methods study *Palliat Med* 21 2 2007 129 137 17344261 10.1177/0269216307076346 112 Orrevall Y. Tishelman C. Herrington M.K. The path from oral nutrition to home parenteral nutrition: a qualitative interview study of the experiences of advanced cancer patients and their families *Clin Nutr* 23 6 2004 1280 1287 15556250 10.1016/j.clnu.2004.04.006 113 Reid J. McKenna H. Fitzsimons D. The experience of cancer cachexia: a qualitative study of advanced cancer patients and their family members *Int J Nurs Stud* 46 5 2009 606 616 19081090 10.1016/j.ijnurstu.2008.10.012 114 Reid J. Psychosocial, educational and communicative interventions for patients with cachexia and their family carers *Curr Opin Support Palliat Care* 8 4 2014 334 338 25144837 10.1097/SPC.000000000000087 PMC4232291 115 Millar C. Reid J. Porter S. Healthcare professionals' response to cachexia in advanced cancer: a qualitative study *Oncol Nurs Forum* 40 6 2013 E393 E402 24161643 10.1188/13.ONF.E393-E402 116 Reid J. McKenna H.P. Fitzsimons D. An exploration of the experience of cancer cachexia: what patients and their families want from healthcare professionals *Eur J Cancer Care (Engl)* 19 5 2010 682 689 19912306 10.1111/j.1365-2354.2009.01124.x 117 Amano K. Maeda I. Morita T. Eating-related distress and need for nutritional support of families of advanced cancer patients: a nationwide survey of bereaved family members *J Cachexia Sarcopenia Muscle* 7 5 2016 527 534 27239421 10.1002/jcsm.12102 PMC4864141 118 Hopkinson J.B. Fenlon D.R. Okamoto I. The deliverability, acceptability, and perceived effect of the Macmillan approach to weight loss and eating difficulties: a phase II, cluster-randomized, exploratory trial of a psychosocial intervention for weight- and eating-related distress in people with advanced cancer *J Pain Symptom Manage* 40 5 2010 684 695 20678895 10.1016/j.jpainsymman.2010.02.015 119 Hopkinson J.B. Fenlon D.R. Foster C.L. Outcomes of a nurse-delivered psychosocial intervention for weight- and eating-related distress in family carers of patients with advanced cancer *Int J Palliat Nurs* 19 3 2013 116 118-23 23665569 10.12968/ijpn.2013.19.3.116 120 Hopkinson J.B. Richardson A. A mixed-methods qualitative research study to develop a complex intervention for weight loss and anorexia in

advanced cancer: the family approach to weight and eating Palliat Med 29 2 2015 164 176 25501313 10.1177/0269216314556924 121 Fearon K.C. Cancer cachexia: developing multimodal therapy for a multidimensional problem Eur J Cancer 44 8 2008 1124 1132 18375115 10.1016/j.ejca.2008.02.033 122 Reckman G.A.R. Gomes-Neto A.W. Vonk R.J. Anabolic competence: assessment and integration of the multimodality interventional approach in disease-related malnutrition Nutrition 65 2019 179 184 31170682 10.1016/j.nut.2019.03.010 123 Maddocks M. Hopkinson J. Conibear J. Practical multimodal care for cancer cachexia Curr Opin Support Palliat Care 10 4 2016 298 305 27635765 10.1097/SPC.0000000000000241 PMC5087573 124 Atherton P.J. Smith K. Muscle protein synthesis in response to nutrition and exercise J Physiol 590 5 2012 1049 1057 22289911 10.1113/jphysiol.2011.225003 PMC3381813 125 Uster A. Ruehlin M. Mey S. Effects of nutrition and physical exercise intervention in palliative cancer patients: a randomized controlled trial Clin Nutr 37 4 2018 1202 1209 28651827 10.1016/j.clnu.2017.05.027 126 Lu Z. Fang Y. Liu C. Early interdisciplinary supportive care in patients with previously untreated metastatic esophagogastric cancer: a phase III randomized controlled trial J Clin Oncol 39 7 2021 748 756 33417481 10.1200/JCO.20.01254 PMC8078238 127 Dev R. Hui D. Chisholm G. Hypermetabolism and symptom burden in advanced cancer patients evaluated in a cachexia clinic J Cachexia Sarcopenia Muscle 6 1 2015 95 98 26136416 10.1002/jcsm.12014 PMC4435101 128 Fallon M. Walker J. Colvin L. Pain management in cancer center inpatients: a cluster randomized trial to evaluate a systematic integrated approach – the Edinburgh Pain Assessment and management tool J Clin Oncol 36 13 2018 1284 1290 29543567 10.1200/JCO.2017.76.1825 PMC5929219 129 Haun M.W. Estel S. Rücker G. Early palliative care for adults with advanced cancer Cochrane Database Syst Rev 6 6 2017 Cd011129 28603881 10.1002/14651858.CD011129.pub2 PMC6481832 130 Hui D. Finlay E. Buss M.K. Palliative oncologists: specialists in the science and art of patient care J Clin Oncol 33 20 2015 2314 2317 25918292 10.1200/JCO.2014.60.3274 PMC4979217 131 Dykewicz C.A. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients Clin Infect Dis 33 2 2001 139 144 (Adapted from: Gross PA, Barrett TL, Dellinger EP et al. Purpose of quality standards for infectious diseases. Clin Infect Dis. 1994;18:421) 11418871 10.1086/321805 132 Malmstrom T.K. Miller D.K. Simonsick E.M. SARC-F: a symptom score to predict persons with sarcopenia at risk for poor functional outcomes J Cachexia Sarcopenia Muscle 7 1 2016 28 36 27066316 10.1002/jcsm.12048 PMC4799853 133 Mourtzakis M. Prado C.M. Lieffers J.R. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care Appl Physiol Nutr Metab 33 5 2008 997 1006 18923576 10.1139/H08-075 134 Edemekong P. Bomgaars D. Sukumaran S. Levy S.B. Activities of daily living StatPearls [Internet] 2020 Treasure Island, FL StatPearls Publishing Available at: <https://www.ncbi.nlm.nih.gov/books/NBK470404/> Updated June 26, 2020. Accessed January 22, 2021 29261878 135 Turner-Stokes L. Tonge P. Nyein K. The Northwick Park Dependency Score (NPDS): a measure of nursing dependency in rehabilitation Clin Rehabil 12 4 1998 304 318 9744666 10.1191/026921598669173600 136 Ministry of Health Province of British Columbia. Frailty in older adults – early identification and management. BCGuidelines.ca Available at <https://www2.gov.bc.ca/assets/gov/health/practitioner-pro/bc-guidelines/frailty-gaitspeed.pdf> 2017 Accessed January 27, 2021 137 Ottery F.D. Definition of standardized nutritional assessment and interventional pathways in oncology Nutrition 12 Suppl 1996 S15 S19 8850213 10.1016/0899-9007(96)90011-8 138 Hui D. Bruera E. The Edmonton symptom assessment system 25 years later: past, present, and future developments J Pain Symptom Manage 53 3 2017 630 643 28042071 10.1016/j.jpainsymman.2016.10.370 PMC5337174 139 Nicholas D. Veach T. The psychosocial assessment of the adult cancer patient Prof Psychol Res Pr 31 2000 206 215 140 FACIT Group Functional assessment of anorexia/cachexia treatment (version 4) Available at <https://www.facit.org/measure-english-downloads/faact-english-downloads> 2007 Accessed January 27, 2021 141 Wheelwright S.J. Hopkinson J.B. Darlington A.S. Development of the EORTC QLQ-CAX24, a questionnaire for cancer patients with cachexia J Pain Symptom Manage 53 2 2017 232 242 27810567 10.1016/j.jpainsymman.2016.09.010 Supplementary data Supplementary Material

Manuscript editing support was provided by Angela Corstorphine of Kstorfin Medical Communications Ltd; this support was funded by ESMO.

No external funding has been received for the preparation of these guidelines. Production costs have been covered by ESMO from central funds.

FS reports receipt of unrestricted industry grants to institute for clinical research from Celgene, Fresenius and Helsinn, participation in company-led clinical cachexia trials for Novartis and participation in an advisory role for Helsinn, Mundipharma, Novartis, Fresenius and Kaiku Health (reimbursements to institute); TSS reports receipt of honoraria from Fresenius Kabi; MC reports receipt of payment from Tetra Biopharmaceuticals for helping to write research protocols; JA reports receipt of consultancy fees from Baxter and Danone and honoraria from Berg-Apotheke, Falk, Fresenius Kabi, Nutricia and Roche; CIR reports receipt of funding for independent educational events from Inpharm, Kyowa Kirin, Amgen Europe and Molteni SpA; MAEdvdS reports receipt of honoraria for independent lectures at educational and scientific events organised by Nutricia, Fresenius Kabi and Baxter; all other authors have declared no conflicts of interest.

■ Note: Approved by the ESMO Guidelines Committee: February 2021.